ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BVP Bioscience Vct

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type Share ISIN Share Description
Bioscience Vct LSE:BVP London Ordinary Share GB0031256109 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

B Share Buy-back and Total Voting Rights

20/11/2023 3:20pm

GlobeNewswire Inc.


Bioscience Vct (LSE:BVP)
Historical Stock Chart


From Jan 2023 to Jan 2025

Click Here for more Bioscience Vct Charts.
B Share Buy-back and Total Voting Rights

Transaction in Own Shares and Total Voting Rights and Capital

20 November 2023

Seneca Growth Capital VCT Plc (“The Company”)

B Share Buy-back and Total Voting Rights

The Board of Seneca Growth Capital VCT Plc announces that on 17 November 2023 the Company purchased for cancellation 88,431 B Ordinary Shares of 1p at a gross price of 70.68p per share.

In accordance with the FCA's Disclosure and Transparency Rules sourcebook transitional provision 6, the Company advises that, following this purchase for cancellation, its capital consists of 20,729,286 B Ordinary Shares of 1p each and 8,115,376 Ordinary Shares of 1p each.

The Company does not hold any shares in Treasury.

Therefore, the total number of voting rights in the Company is 28,844,662 which may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

The Company was satisfied that all inside information which the Directors and the Company were previously in receipt of had become publicly available prior to the market purchase being completed. Therefore, the Company was not prohibited from dealing in its own securities.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

1 Year Bioscience Vct Chart

1 Year Bioscience Vct Chart

1 Month Bioscience Vct Chart

1 Month Bioscience Vct Chart

Your Recent History

Delayed Upgrade Clock